Last reviewed 2026-04-23 · How we verify

CK-2017357

CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.

CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility. Used for Hypertrophic cardiomyopathy.

At a glance

Mechanism of action

CK-2017357 works by inhibiting the myosin ATPase activity of cardiac myosin, leading to increased cardiac contractility and improved heart function. This mechanism is thought to be beneficial for patients with heart failure.

Approved indications

• Hypertrophic cardiomyopathy

Common side effects

• dyspnea
• fatigue

Key clinical trials

• A Study for Patients Who Completed VITALITY-ALS (CY 4031) (PHASE3)
• Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (PHASE3)
• Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
• Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis (PHASE2)
• A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication (PHASE2)
• A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
• A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
• Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CK-2017357 CI brief — competitive landscape report
• CK-2017357 updates RSS · CI watch RSS
• Cytokinetics portfolio CI